Chronic Myelogenous Leukemia Diagnosis

NewsGuard 100/100 Score

Those with symptoms of leukemia or Chronic Myelogenous Leukemia (CML) are further investigated to confirm the diagnosis of CML and commence treatment.

The diagnosis is made by a haematologist or a haemato-oncologist – one who specializes in cancers and disorders of the blood. 

Blood tests

A routine blood smear examination as well as blood count evaluation often gives clues to leukemias in general.

The complete blood count (CBC) is a test that measures the levels of different blood cells such as red blood cells, white blood cells, and platelets. Suspected cases of CML are usually first detected after a blood test.

The blood tests reveal abnormally high levels of white blood cells and high blast cell or immature white blood cell count in blood.

Blood biochemistry tests help to determine the liver and kidney functioning and determine the levels of certain minerals and enzymes present in blood.

Bone marrow biopsy

A small sample of bone marrow is taken. This is called bone marrow biopsy.

The bone marrow biopsy is performed under local anesthesia. The physician will numb an area of skin at the back of the hip bone and use a wide bore needle to remove the bone marrow sample.

There may be a little pain and bruising after the procedure. The procedure takes around 15 minutes to complete and may be performed on an outpatient basis.

The bone marrow sample is then smeared onto a glass slide and examined under the microscope. Cancer cells if detected may offer clues as to the type of leukemia – lymphoid (CLL) or myeloid (CML).

Cytogenetic testing

This is a highly specific test that assess the genetic makeup of the cancer cells. The leukemia is caused by severe distinctive DNA mutations.

Some of these are specific for the patient to respond to specific modalities of treatment. Thus cytogenetic testing is important for determining the modality of treatment and drugs to be used for optimum benefit.

For example, 90% of people with chronic myeloid leukaemia have the Philadelphia chromosome. People who have this chromosome are known to respond well to a medicine that belongs to the group tyrosine kinase inhibitors called Imatinib. Some of the tests used for cytogenetic evaluation include PCR and FISH.

Imaging tests

These include X rays, CT scans and MRI scans. CT (computed tomography) scans. These are not diagnostic tests that can confirm presence of CML but may provide clues as to the extent of spread of the cancer to other organs.

MRI scans are mainly useful to check for spread to the brain and spinal cord. Ultrasound examinations may be used to check for abnormal growths in the abdomen.

Staging of CML

Once the diagnosis of a cancer is confirmed, it is staged into stages of the disease progression. Staging helps in planning treatment and predicting the outcome of a cancer.

Most types of cancer are staged based on the size of the tumor and how far it has spread from the origin of the cancer. This system is not useful in leukemias as there are no solid tumours in this case.

For CML there are phases of development of the disease.  CML is divided into 3 groups that help predict outcome of the cancer. These phases are classified based on the number of immature white blood cells or blast cells seen in the blood or bone marrow. The phases are:-

Chronic phase

In this phase there are less than 10% blast cells in blood. Patients usually have mild symptoms and are responsive to standard treatment. Most patients are diagnosed in the chronic phase

Accelerated phase

In this phase there are more than 10% and less than 20% blast cells in blood or bone marrow. In this phase there are symptoms of fever, weight loss and poor appetite. The response to usual drug treatment is poorer than chronic phase.

Blast phase

This phase is also called acute phase or blast crisis. In this phase there are over 20% blast cells in blood or bone marrow. At this point the CML acts like acute leukemia because of its aggressiveness and rapid growth.

Further Reading

Last Updated: Jan 24, 2023

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2023, January 24). Chronic Myelogenous Leukemia Diagnosis. News-Medical. Retrieved on March 04, 2024 from

  • MLA

    Mandal, Ananya. "Chronic Myelogenous Leukemia Diagnosis". News-Medical. 04 March 2024. <>.

  • Chicago

    Mandal, Ananya. "Chronic Myelogenous Leukemia Diagnosis". News-Medical. (accessed March 04, 2024).

  • Harvard

    Mandal, Ananya. 2023. Chronic Myelogenous Leukemia Diagnosis. News-Medical, viewed 04 March 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment